Targeted anti-cancer agents Poziotinib, goes on phase 2 to expand indications for Breast cancer

제목 없음 Targeted anti-cancer agents Poziotinib, goes on phase 2 to expand indications for Breast cancer SEOUL, South Korea-Hanmi pharmaceutical (128940), 27/2/2015 Hanmi Pharm (CEO, Lee Gwan-Sun, www.hanmi.co.kr) begins to expand indications for targeted anti-cancer agents, Poziotinib which is co-developing with Anticancer Drug Development Agency. Hanmi Pharm recently revealed that Hanmi has approved by MFDS (Ministry of Food and Drug Safety) for conducting phase 2 clinical trials to stage 4 breast cancer patients by using Poziotinib. Also, Hanmi will begin clinical trial with more than 70 breast cancer patients who have failed by using more than 2 kinds of HER-2 targeted anti-cancer therapy in 7 institutions including Samsung Seoul Hospital. Poziotinib is a pan-HER inhibitor which targets the HER protein, observed in several cancers. Hanmi conducted clinical trial for lung cancer / head and neck cancer. Hanmi plans to expand Poziotinib’s indications to breast cancer with this clinical trial. Pre-clinical and phase 2 clinical trial results showed that Poziotinib is effective in HER-2 positive breast cancer which showed resistance to existing anti-cancer drug. Hanmi signed technology transfer contract of Poziotinib with Chinese Luye Pharm in August,2014. From now on, Luye will be responsible for development and sales for Poziotinib in China. Hanmi Pharm’s clinical team director Jung Jin-A mentioned that “We plan to confirm treatment efficacy widely from HER-2-positive cancer patients who are suffering from existing anti-cancer drug tolerance through Poziotinib’s indication expending. We will accelerate clinical trial to offer new treatment opportunity to cancer patients.” PREV Hanmi Pharmaceutical initiated phase I clinical trial of first in class weekly insulin in US LIST NEXT Hanmi Out-Licenses Poziotinib, a Promising, Irreversible, pan-erbB Inhibitor being investigated for the Treatment of Cancer, to Spectrum Pharmaceuticals

The release as fetched from its publisher. hanmipharm.com ↗